ACCESS

EU-JAMRAI2 aims to provide substantial assistance to Member States (MS) in the development and periodic updating of their National Action Plans (NAPs) on Antimicrobial Resistance (AMR). By offering direct and significant support, the initiative seeks to enhance the capacity of MS to effectively tackle AMR within their healthcare systems. Secondly, EU-JAMRAI2 endeavors to bolster the responsiveness and coordination of health systems across the Union, thereby safeguarding individuals from the threat of AMR. Through improved collaboration and streamlined efforts, the initiative aims to fortify the resilience of healthcare systems against the proliferation of drug-resistant infections.

One of the main objectives of EU-JAMRAI2 in this field is to improve access to selected AMR-related products both for human and veterinarian use:

Focus products

The participating countries in EU-JAMRAI 2 that are working on strengthening access have identified clinically important antibiotics and veterinary vaccines with a vulnerable supply. The products reflect the national context in terms of clinical needs, availability and resistance situation. Products may change during the project.

Please click on a turquoise country to see the national focus products.

France

Amoxicillin, clavulanic acid (human)
Aztreonam (human)
Benzathine benzylpenicillin (human)
Cefixime (human)
Fosfomycin (human)
Phenoxymethylpenicillin (human)
Rifampicin (human)
Rifampicin, isoniazid (human)
Rifampicin, isoniazid, pyrazinamide (human)
Rifapentine (human)
Sulfamethoxazole, trimethoprim (human)
Vaccine for turkey rhinotracheitis virus (Veterinary)
Vaccine for clostridium related diseases in ruminant (Veterinary)
Vaccines for Muscovy ducks against Derszy disease ± parvovirosis (Veterinary)

Download a full list

Spain

Amikacin (human)
Aztreonam (human)
Benzathine phenoxymethylpenicillin (human)
Cefadroxil (human)
Trimetoprim and Sulfamethoxazole (human)
Oxytetracycline (veterinary)
Vaccines for hemorrahagic enteritis in turkeys (veterinary)
Vaccines for respiratory disease complex in cattle/sheep/goats (veterinary)
Vaccines for coccidiosis (veterinary)

Download a full list

Belgium

Cefadroxil OR Cefalexin (human)
Daptomycin (human)
Phenoxymethylpenicillin (human)
Procaine-benzylpenicillin OR Benzathine Benzylpenicillin (human)
Rifampicin (human)
Sulfadiazine (human)
Sulfamethoxazole + trimethoprim (human)
Thiamphenicol (human)
Amoxicillin (veterinary)
Cefalexin (veterinary)

Download a full list

Bulgaria

Amphotericin B “liposomal” (human)
Benzylpenicillin (human)
Ceftaroline (human pediatric only)
Daptomycin (human)
Eravacycline (human)
Erythromycin (human)
Fosfomycin (human)
Nitrofurantoin (human)
Phenoxymethylpenicillin (human)
Tobramycin (human)

Download a full list

Denmark

Flucloxacillin (human, pediatric)
Fosfomycin (human)
Nitrofurantoin (human)
Pivmecillinam (human)
Ampicillin (human and veterinay)
Benzylpenicillin (/procaine benzylpenicillin) (human and veterinary)
Gentamicin (human and veterinary)
Phenoxymethylpenicillin (human and veterinary)
Rifampicin (human and veterinary)
Amoxicillin (veterinary)
Fucidic acid (veterinary)
Sulfadiazine, Trimethoprim (veterinary)

Download a full list

Finland

Amoxicillin (Human)
Benzylpenicillin sodium (Human)
Nitrofurantoin (Human)
Phenoxymethylpenicillin (Human)
Rifampicin (Human)
Cloxacillin (veterinary)
ERM vaccine for fish (veterinary)
Gentamicin (veterinary)
Phenoxymethylpenicillin (veterinary)
Procaine benzylpenicillin (veterinary)
Trimethoprim, Sulfonamide (veterinary)

Download a full list

Iceland

Amoxicillin (human and veterinary)
Amoxicillin and beta-lactamase inhibitor (human and veterinary)
Benzylpenicillin / Procaine benzylpenicillin (human and veterinary)
Cefalexin (human and veterinary)
Dicloxacillin (human and veterinary)
Phenoxymethylpenicillin (human and veterinary)
Sulfamethoxazole and trimethoprim / Sulfadiazine and trimethoprim (human and veterinary)
Clindamycin (veterinary)
Enrofloxacinum (veterinary)
Oxytetracycline ( veterinary)

Download a full list

Italy

Amikacin (human)
Azithromycin (human)
Benzathine benzylpenicillin (human)
Chloramphenicol (human)
Clarithromycin (human)
Piperacillin, tazobactam (human)

Download a full list

Netherlands

Amoxicillin (Human)
Amoxicillin, clavuanic acid (Human)
Benzathine benzylpenicillin (Human)
Benzylpenicillin (Human)
Cefazolin (Human)
Ceftazidim (Human)
Ciprofloxacin (Human)
Clindamycin (Human)
Cotrimoxazol (Human)
Doxycycline (Human)
Metronidazole (Human)
Phenoxymethylpenicillin (Human)
Rifampicin (Human)
Innovative vaccines against emerging and novel animal diseases (veterinary)

Download a full list

Norway

Benzylpenicillin (human)
Dicloxacillin (human)
Doxycycline (human)
Erythromycin or clarithromycin (human)
Flucloxacillin (human)
Gentamicin (human)
Phenoxymethylpenicillin (human)
Pivmecillinam (human)
Spectinomycin. (Human)
TB antibiotics from WHO guidelines (human)
Procaine benzylpenicillin (veterinary)
Salmon vaccines (veterinary)

Download a full list

Poland

Azithromycin (Human)
Aztreonam (Human)
Benzathine benzylpenicillin (Human)
Benzylpenicilin natrium (Human)
Cefalexin (Human)
Flucloxacillin (Human)
Minocycline (Human)
TB antibiotics from WHO guidelines (Human)

Download a full list

Slovenia

Amoxicillin (human)
Cefuroxime (human)
Clarithromycin (human)
Flucloxacillin (human)
Gentamicin (human and veterinary)
Phenoxymethylpenicillin (human)
Tuberculosis antibiotics (human)
Vaccination for dengue (human)
Vaccine for erysipelothrix (Veterinary)

Download a full list

Sweden

Amoxicillin (human)
Ceftibuten (human)
Cefixime (human)
Colistin (human)
Phenoxymethylpenicillin (human)
Procaine benzylpenicillin (veterinary)
Rifampicin (human)
Temocillin (human)
Trimethoprim, sulfamethoxazole (human)
Trimethoprim, sulfadiazine (veterinary)

Download a full list

Malta

Amoxicillin (human)
Aztreonam (human)
Cefalexin (human)
Cefazolin (human)
Clindamycin (human)
Co-trimoxazole (human)
Fosfomycin (human)
Temocillin (human)
Oxytetracycline (Veterinary)
Vaccine for bovine parainfluenza virus, bovine respiratory syncytial virus and pasteurella (Veterinary)
Vaccine for bovine rotavirus, bovine coronavirus and escherichia (Veterinary)

Download a full list

Greece

Aztreonam (human)
Tobramycin (human)

*Greece joined the Access work package after the project start and thus may have fewer focus products

Download a full list

Latvia

Aztreonam (Human)
Daptomycin (Human)
Fosfomycin (Human)
Phenoxymethylpenicillin (Human)
Pivmecillinam (Human)
TB antibiotics from WHO guideline (Human)

*Latvia joined the Access work package after the project start and thus may have fewer focus products

Download a full list

Antibiotic assessment guide

Here you find the methodology that was applied by the countries to identify their focus products for human use (the veterinary methodology will be added here shortly).

Download the antibiotic assessment guide

Download the antibiotic assessment template

Barriers to access

For the focus products participants will identify and analyse the specific barriers to access, within their national contexts, in collaboration with national and European stakeholders.

Targeted interventions

Targeted at the barriers to access, participating countries aim to identify, develop and support the implementation national, regional, and European interventions to strengthen access to the specific focus products.

New Products

When it comes to strengthening access to new technologies, like novel antibiotics and bacteriophages, EU-JAMRAI 2 are aiming to assist DG HERA and other European bodies in their efforts and serve as a discussion forum for these questions.

Read the conference report from our kick-off event, “Sustainable implementation of human phage therapy across the EU”, held in Brussels, Belgium on March 1st, 2024.

Marketed antibiotics for tuberculosis in EU/EEA countries and UK

This spreadsheet contains an extract of the Article 57 database received from EMA with information up to July 27, 2025. This may be helpful for those individuals procuring antibiotic for tuberculosis to better understand which products are marketed, where they are marketed, under which regulatory pathway, and the contact information for the marketing authorization holder.

Download spreadsheet

Please note that the terms below apply.

The information provided is based on data held in the Article 57 database. This data is submitted by holders of marketing authorisations (MAHs) for medicines in the European Union and the European Economic Area. The provided data reflects the state of the Article 57 database on 27 July 2025 as extracted on 28 July 2025.
A medicinal product may contain multiple pharmaceutical products (administrable pharmaceutical forms), e.g. tablets and film-coated tablets, or tablets with different compositions as part of a same medicinal product. These forms are listed in sequence and separated by a “|” sign.
MAHs must submit information to the European Medicines Agency (EMA) on authorised medicines and keep this information up-to-date in accordance with EU pharmaceutical regulation.
The following Guidance can be consulted for more information on how and when Article 57 data elements are to be populated: Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the European Medicines Agency in accordance with Article 57(2) of Regulation (EC) No. 726/2004, Chapter 3.II: XEVPRM User Guidance.
Further information on the Article 57 database can be found here.